Literature DB >> 32218665

Can concordance between actual care received and a pathway map be measured on a population level in Ontario? A pilot study.

K Forster1, K Tsang1, S Li1, L Ieraci1, P Murray1, K J Woltman1, D Chmelnitsky1, C M B Holloway1,2, E D Kennedy1,3,4.   

Abstract

Background: Clinical pathways are associated with improved adherence to clinical guidelines; however, most studies have evaluated pathways for a single intervention at a single institution. The objective of the present study was to develop and evaluate a method of measuring concordance with a population-based clinical pathway map to determine if that method could be feasible for assessing overall health system performance.
Methods: Patients with stage ii or iii colon cancer diagnosed in 2010 were identified, and clinical data were obtained through linkages to administrative databases. Pathway concordance was defined a priori based on receipt of key elements of the Ontario Health (Cancer Care Ontario) colorectal pathway maps. For stages ii and iii colon cancer alike, concordance was reported as the proportion of patients receiving care that followed the predefined key elements of the pathway map. Regression analysis was used to identify predictors of concordant care.
Results: Our study identified 816 patients with stage ii and 800 patients with stage iii colon cancer. Of the patients with stage ii disease, 70% (n = 571) received concordant care. Of the patients with stage iii disease, results showed high concordance for all key elements except receipt of chemotherapy, leading to an overall concordance rate of 39% for that cohort. Conclusions: Our method of measuring concordance was feasible on a population-based level, but future studies to validate it and to develop more sophisticated methods to measure concordance in larger cohorts and various disease sites are necessary. Measurement of clinical pathway concordance on a population-based level has the potential to be a useful tool for assessing system performance. 2020 Multimed Inc.

Entities:  

Keywords:  Clinical pathways; colon cancer; concordance; quality improvement; system performance

Mesh:

Year:  2020        PMID: 32218665      PMCID: PMC7096194          DOI: 10.3747/co.27.5349

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  9 in total

1.  Using cancer registry data for survival studies: the example of the Ontario Cancer Registry.

Authors:  Stephen Hall; Karleen Schulze; Patti Groome; William Mackillop; Eric Holowaty
Journal:  J Clin Epidemiol       Date:  2005-10-03       Impact factor: 6.437

2.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

Authors:  Hude Quan; Bing Li; Chantal M Couris; Kiyohide Fushimi; Patrick Graham; Phil Hider; Jean-Marie Januel; Vijaya Sundararajan
Journal:  Am J Epidemiol       Date:  2011-02-17       Impact factor: 4.897

Review 3.  Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs.

Authors:  Thomas Rotter; Leigh Kinsman; Erica James; Andreas Machotta; Holger Gothe; Jon Willis; Pamela Snow; Joachim Kugler
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Repeated faecal occult blood testing is associated with decreased advanced colorectal cancer risk: A population-based study.

Authors:  Paul D James; Linda Rabeneck; Lingsong Yun; Lawrence Paszat; Nancy N Baxter; Anand Govindarajan; Lilia Antonova; Jill M Tinmouth
Journal:  J Med Screen       Date:  2017-09-01       Impact factor: 2.136

Review 5.  Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review.

Authors:  David A Etzioni; Anthony B El-Khoueiry; Robert W Beart
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

6.  What is a clinical pathway? Development of a definition to inform the debate.

Authors:  Leigh Kinsman; Thomas Rotter; Erica James; Pamela Snow; Jon Willis
Journal:  BMC Med       Date:  2010-05-27       Impact factor: 8.775

7.  The quality of the evidence base for clinical pathway effectiveness: room for improvement in the design of evaluation trials.

Authors:  Thomas Rotter; Leigh Kinsman; Erica James; Andreas Machotta; Ewout W Steyerberg
Journal:  BMC Med Res Methodol       Date:  2012-06-18       Impact factor: 4.615

8.  Structured syncope care pathways based on lean six sigma methodology optimises resource use with shorter time to diagnosis and increased diagnostic yield.

Authors:  Leon Martens; Grahame Goode; Johan F H Wold; Lionel Beck; Georgina Martin; Christian Perings; Pelle Stolt; Lucas Baggerman
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

9.  A dynamic clinical pathway for the treatment of patients with early breast cancer is a tool for better cancer care: implementation and prospective analysis between 2002-2010.

Authors:  Peter A van Dam; Gerda Verheyden; Alessa Sugihara; Xuan B Trinh; Herman Van Der Mussele; Hilde Wuyts; Luc Verkinderen; Jan Hauspy; Peter Vermeulen; Luc Dirix
Journal:  World J Surg Oncol       Date:  2013-03-16       Impact factor: 2.754

  9 in total
  2 in total

1.  Development of population-level colon cancer pathway concordance measures and association with survival.

Authors:  Luciano Ieraci; Maria Eberg; Katharina Forster; Paula M Murray; Emmett Borg; Steven Habbous; Ali Vahit Esensoy; Erin Kennedy; Claire M B Holloway
Journal:  Int J Cancer       Date:  2022-03-03       Impact factor: 7.316

2.  A Quality Improvement Approach to Influence Value-based Mucolytic Use in the PICU.

Authors:  Holly Catherine Gillis; Kevin Dolan; Cheryl L Sargel; R Zachary Thompson; Jeffrey E Lutmer
Journal:  Pediatr Qual Saf       Date:  2021-07-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.